The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
A clinical study of WJ01024 in subjects with advanced cancer in China, to evaluate the
safety, tolerability, PK and efficacy of WJ01024. This study includes a dose escalation part
and a dose expansion part. Patients receive WJ01024 on Day 1 and Day 3 of each week, 4 weeks
as a cycle, until disease progression, or intolerable toxicity , withdrawal of consent, or
end of the study, whichever occurs first.